Nature September 2020 PMID 32908313

Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.

Zhong Y Yeow, Bramwell G Lambrus, Rebecca Marlow, Kevin H Zhan, Mary-Anne Durin, Lauren T Evans, Phillip M Scott, Thao Phan, Elizabeth Park, Lorena A Ruiz, Daniela Moralli, Eleanor G Knight, Luned M Badder, Daniela Novo, Syed Haider

Full text PDF Download social card

Mentions

Peak: 11 in Sep 2020

across 5 sources since Sep 2020

Extended reach

59,996

potential audience

Total likes

Video views

669

Mentions per month

Sep 2020 – Oct 2021

Where it's discussed

X / Twitter18 posts
News14 articles
Reddit4 posts
Blogs3 articles
YouTube2 videos

AI synopsis

What people are saying

This collection reflects a positive and highly interested response, with many posters praising the work and its potential impact, such as calling it a 'game-changer,' while also sharing specific details about how targeting TRIM37 could lead to new therapies. The tone and choice of words reveal a high regard for the study's significance and potential for clinical impact.

AgreementModerate agreement

Most discussions express support and positivity towards the research, recognizing its significance, evidenced by comments like 'Great work' and acknowledgment of the article's contribution.

InterestHigh interest

Many posts show high curiosity and enthusiasm, with phrases like 'exciting discovery' and highlighting the potential for new therapeutic avenues.

EngagementModerate engagement

Posts demonstrate active engagement by sharing appreciation, tagging researchers, and referencing the study's implications, indicating at least moderate depth of involvement.

ImpactHigh impact

Several discussions emphasize the importance of this research for advancing breast cancer treatment, suggesting it could be a breakthrough or influential in the field.

Abstract in brief

The study explores how targeting TRIM37, a protein overexpressed in some breast cancers with 17q23 amplification, can lead to cell death by inducing centrosome dysfunction, which is crucial for proper cell division.
Inhibiting PLK4, a kinase responsible for centrosome formation, causes centrosome depletion specifically in cancer cells with high TRIM37 levels, leading to mitotic catastrophe and potential cancer treatment.
Overexpression of TRIM37 disrupts centrosome maturation and increases genomic instability by delaying key steps in cell division, suggesting that TRIM37-driven instability could be a target for therapeutic intervention in these cancers.]

Read the full abstract

All mentions

Targeting TRIM37 to Induce Centrosome Dysfunction in Breast Cancer Treatment

Breast cancer is one of the most well-known cancers. This video explains how targeting TRIM37, overexpressed in certain breast cancers, can induce centrosome dysfunction leading to cell death, offering potential…

24Genetics TV · Oct 5, 2021 393 views

Targeting TRIM37 to Induce Centrosome Dysfunction in 17q23-amplified Breast Cancer

This study explores how targeting TRIM37, overexpressed in some breast cancers with 17q23 amplification, induces centrosome dysfunction leading to cell death. Inhibiting PLK4 causes centrosome depletion and mitotic…

24Genetics TV · Oct 5, 2021 276 views